Twist Bioscience Co. (NASDAQ:TWST) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $51.90.

Several research firms have recently weighed in on TWST. Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird boosted their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. Wolfe Research began coverage on Twist Bioscience in a report on Friday. They issued an “outperform” rating and a $60.00 price target for the company. Scotiabank increased their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Finally, Barclays dropped their price objective on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 14,334 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the sale, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. This trade represents a 2.37 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paula Green sold 3,310 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $143,025.10. Following the transaction, the senior vice president now directly owns 84,585 shares of the company’s stock, valued at $3,654,917.85. The trade was a 3.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,787 shares of company stock worth $4,584,508. 3.92% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently modified their holdings of the business. Caprock Group LLC raised its holdings in shares of Twist Bioscience by 2.9% during the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after purchasing an additional 220 shares during the last quarter. Signaturefd LLC raised its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. Arizona State Retirement System grew its stake in Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after acquiring an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Twist Bioscience by 3.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock worth $457,000 after purchasing an additional 312 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Twist Bioscience by 2.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after buying an additional 363 shares during the last quarter.

Twist Bioscience Trading Up 0.2 %

Twist Bioscience stock opened at $47.50 on Friday. The business’s 50 day simple moving average is $44.94 and its 200 day simple moving average is $46.63. Twist Bioscience has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a market cap of $2.82 billion, a price-to-earnings ratio of -13.19 and a beta of 1.82.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.